Literature DB >> 2990673

Transferrin-like activity produced by murine malignant T-lymphoma cell lines.

S Kitada, E F Hays.   

Abstract

Transferrin has been considered to be an essential requirement for hematopoietic cell proliferation in culture. We have isolated two cloned lymphoma cell lines, SL 12.1 and SL 12.4, which grow and adapt in serum-free medium without added transferrin. Antibody to the transferrin receptor blocks the growth of these cells. We have also demonstrated that transferrin-free conditioned medium from the cells will compete with transferrin for binding. Furthermore, conditioned medium from SL 12.1 and SL 12.4 cells induces and supports exponential growth of a transferrin-dependent lymphoma cell line, SL 12. We conclude that these two transferrin-independent cloned lines produce transferrin-like activity which plays a crucial role for cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2990673

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Growth factor regulation of proliferation in primary cultures of small intestinal epithelium.

Authors:  C Booth; G S Evans; C S Potten
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

2.  Species specificity of iron delivery in hybridomas.

Authors:  C R Ill; T Brehm; B K Lydersen; R Hernandez; K G Burnett
Journal:  In Vitro Cell Dev Biol       Date:  1988-05

3.  Growth of human tumor cell lines in transferrin-free, low-iron medium.

Authors:  V Neumannova; D R Richardson; K Kriegerbeckova; J Kovar
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-09       Impact factor: 2.416

4.  Transferrin synthesis by small cell lung cancer cells acts as an autocrine regulator of cellular proliferation.

Authors:  M Vostrejs; P L Moran; P A Seligman
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

5.  Autocrine growth induced by transferrin-like substance in bladder carcinoma cells.

Authors:  H Tanoguchi; M Tachibana; M Murai
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.